Date: 2014-08-26
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9 in Washington
Company: Cubist Pharmaceuticals (USA - MA)
Product: Sivextro™ (tedizolid phosphate)
Action mechanism:
Disease: acute bacterial skin and skin structure infections (ABSSSI)
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On August 26, 2014, Cubist Pharmaceuticals announced that it will present new data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9 in Washington. Noteworthy presentations will include data on Sivextro™ (tedizolid phosphate), recently approved by the FDA for acute bacterial skin and skin structure infections (ABSSSI). Poster: Efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections caused by Staphylococcus aureus—pooled analysis of two Phase 3 trials. Poster L-1732. Presenter: C. DeAnda, Vice President, Clinical, Cubist Pharmaceuticals Poster: Clinical response with tedizolid versus linezolid by infection type and lesion size/location: a pooled analysis of two Phase 3 acute bacterial skin and skin structure infection studies. Poster L-1733. Presenter: C. DeAnda, Vice President, Clinical, Cubist Pharmaceuticals. Poster: Susceptibility testing of a novel oxazolidinone, tedizolid, using linezolid as a surrogate agent. Poster F-1607. Presenter: G. Zurenko, ZML Consulting, Kalamazoo, MI. Poster: Results of the Surveillance of Tedizolid Activity and Resistance (STAR) program: in vitro susceptibility of Gram-positive pathogens collected in 2009 to 2012 from the United States and Europe. Poster C-829. Presenter: Paul A. Bien, MS, Cubist Pharmaceuticals.
